Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, First-in-Human, Phase 1/2 Dose Escalation and Expansion Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

NCT07300241 is registered in ClinicalTrials.gov with Neomorph, Inc as lead sponsor.

NCT NCT07300241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07300241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, First-in-Human, Phase 1/2 Dose Escalation and Expansion Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Lead sponsor
Neomorph, Inc
Phase
Phase 1
Overall status
Recruiting
Start date
December 19, 2025
Completion date
September 30, 2027
Enrollment
30 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

ccrcc, clear cell renal cell carcinoma, clear cell renal cell carcinoma metastatic, kidney cancer metastatic, kidney cancers, rcc, renal cell carcinoma, vhl-associated clear cell renal cell carcinoma, vhl-associated renal cell carcinoma